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Colorectal cancer patients with high levels of tumor-
infiltrating T cells have better survival than patients with
low levels. It is not clear whether the T cells are directly
responsible for improved prognosis or are a sign of a
tumor that is more responsive to conventional cancer
therapies. If tumor infiltrating T cell numbers are asso-
ciated with improved outcome, then we hypothesize that
increasing T cell infiltrates using immunotherapy will
improve the efficacy of chemoradiation. To test this
hypothesis, we established CT26 colorectal carcinomas
subcutaneously in immunocompetent BALB/c mice.
Tumors were treated with 20Gy of radiation in a single
fraction delivered using a clinical linear accelerator. To
increase T cell infiltration into the tumor, an oral anti-
TGFb type I receptor small molecule inhibitor was given
for one week prior to radiation. Outcomes included tumor
kinetics, survival, and immune infiltrate measured by flow
cytometry. TGFb inhibition increased total T cells, acti-
vated CD8 T cells, and reduced inhibitory T regulatory
cell tumor infiltrate in the tumor prior to radiation ther-
apy. Radiation in mice pretreated with TGFb inhibitor
exhibited improved survival compared to either modality
alone. In vitro clonogenic assay demonstrated equivalent
radiosensitivity in control and TGFb-inhibited cells at
doses >6Gy. Small molecule penetrance measured using
quantitative fluorimetry for FITC-dextran was equivalent
in both treated and untreated groups. In vivo depletion of
CD8 cells abrogated the efficacy of both radiation and
TGFb inhibition plus radiation. Therapy aimed at optimiz-
ing the immune environment holds promise for those col-
orectal cancer patients with poor immune infiltrates. Our
preliminary data suggests TGFb inhibition is a therapeutic
strategy to alter tumor immune infiltrates and improve the
efficacy of conventional therapies. Further studies are
needed to determine the mechanism by which increased
immune infiltrates improves outcome.
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